ONCS(Delisted)
OncoSec Medical·NASDAQ
--
--(--)
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ONCS
Oncosec Medical Incorporated
A biotechnology company focused on developing intratumoral immunotherapies
820 Bear Tavern Road, Ewing, NJ 08628-1021
--
Oncosec Medical Incorporated was incorporated on February 8, 2008 under the laws of the State of Nevada. The Company is a late-stage immuno-oncology company focused on the design, development and commercialization of innovative, proprietary, intra-tumor DNA-based therapies to stimulate and enhance the anti-tumor immune response for the treatment of cancer. Their core technology platform, ImmunoPulse, is a drug device treatment model platform consisting of a proprietary intra-tumor electroporation (EP) delivery device (OMS EP device) and a proprietary DNA plasmid delivery and application method that triggers instantaneous expression of target proteins in cells. The OMS EP device is designed to deliver plasmid DNA-encoded drugs directly into solid tumors and promote immune responses against cancer.
Company Financials
EPS
ONCS has released its 2023 Q2 earnings. EPS was reported at -2.65, versus the expected -1.31, missing expectations. The chart below visualizes how ONCS has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
Related Symbols
You can ask Aime
No Data
